Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
Department for BioMedical Research, University of Bern, 3008 Bern, Switzerland.
Int J Mol Sci. 2024 Jun 6;25(11):6257. doi: 10.3390/ijms25116257.
Although glaucoma is a leading cause of irreversible blindness worldwide, its pathogenesis is incompletely understood, and intraocular pressure (IOP) is the only modifiable risk factor to target the disease. Several associations between the gut microbiome and glaucoma, including the IOP, have been suggested. There is growing evidence that interactions between microbes on the ocular surface, termed the ocular surface microbiome (OSM), and tear proteins, collectively called the tear proteome, may also play a role in ocular diseases such as glaucoma. This study aimed to find characteristic features of the OSM and tear proteins in patients with glaucoma. The whole-metagenome shotgun sequencing of 32 conjunctival swabs identified Actinobacteria, Firmicutes, and Proteobacteria as the dominant phyla in the cohort. The species was only found in healthy controls, and their conjunctival microbiomes may be enriched in genes of the phospholipase pathway compared to glaucoma patients. Despite these minor differences in the OSM, patients showed an enrichment of many tear proteins associated with the immune system compared to controls. In contrast to the OSM, this emphasizes the role of the proteome, with a potential involvement of immunological processes in glaucoma. These findings may contribute to the design of new therapeutic approaches targeting glaucoma and other associated diseases.
尽管青光眼是全球导致不可逆性失明的主要原因之一,但它的发病机制尚未完全阐明,而眼压(IOP)是唯一可针对该疾病进行调整的风险因素。已经有几项关于肠道微生物组与青光眼之间的关联的研究,包括眼压。越来越多的证据表明,眼表微生物组(OSM)和泪液蛋白之间的相互作用,这些微生物被称为眼表微生物组(OSM),而泪液蛋白则被称为泪液蛋白质组,也可能在青光眼等眼部疾病中发挥作用。本研究旨在寻找青光眼患者的 OSM 和泪液蛋白的特征。对 32 个结膜拭子的全宏基因组鸟枪法测序确定了放线菌、厚壁菌门和变形菌门为该队列中的主要菌群。仅在健康对照组中发现了 ,与青光眼患者相比,其结膜微生物组中可能富含磷脂酶途径的基因。尽管 OSM 存在这些微小差异,但与对照组相比,患者的许多与免疫系统相关的泪液蛋白含量增加。与 OSM 相反,这强调了蛋白质组的作用,免疫过程可能与青光眼有关。这些发现可能有助于设计针对青光眼和其他相关疾病的新治疗方法。